$18.6 M

FCSC Mkt cap, 10-Jun-2019
Fibrocell Science Net income (FY, 2018)-10.3 M
Fibrocell Science Cash, 31-Dec-201814.4 M

Fibrocell Science Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

200.0k180.0k492.0k355.0k

Revenue growth, %

(10%)173%(28%)

Cost of goods sold

8.1m722.0k697.0k

Gross profit

(7.9m)(230.0k)(342.0k)

Gross profit Margin, %

(3926%)(47%)(96%)

R&D expense

12.6m10.0m8.4m6.5m6.0m

General and administrative expense

10.1m11.3m9.8m6.7m6.4m

Operating expense total

22.7m21.3m18.2m13.3m12.4m

EBIT

(30.5m)(37.4m)(26.5m)(19.0m)

EBIT margin, %

(15251%)(7603%)(7459%)

Interest expense

228.0k828.0k771.0k

Interest income

2.0k8.0k

Pre tax profit

(31.6m)(34.5m)(15.3m)(16.2m)(10.3m)

Income tax expense

Net Income

(31.6m)(25.6m)(34.5m)(15.3m)(16.2m)(10.3m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

194.0k137.0k79.0k16.0k87.0k215.0k

Cost of goods sold

1.9m793.0k547.0k512.0k147.0k162.0k204.0k18.0k392.0k287.0k

Gross profit

47.0k(25.0k)(125.0k)(2.0k)(305.0k)(72.0k)

Gross profit Margin, %

24%(18%)(158%)(12%)(351%)(33%)

R&D expense

8.4m7.4m2.6m2.9m3.7m4.2m2.4m1.6m1.5m1.7m1.7m1.6m3.1m

General and administrative expense

2.9m2.8m3.5m2.8m3.6m2.5m2.5m2.7m1.5m1.7m2.0m1.6m3.2m

Operating expense total

11.3m10.3m6.1m5.7m7.3m6.7m4.9m4.4m2.9m3.3m3.6m3.3m6.3m

EBIT

(13.1m)(11.0m)(6.6m)(6.2m)(6.9m)(7.4m)(6.8m)(6.7m)(10.3m)(5.0m)(4.5m)(5.0m)(4.6m)(3.0m)(6.1m)

EBIT margin, %

(3538%)(5372%)(8637%)(41675%)(11861%)(2333%)

Interest expense

46.0k183.0k185.0k273.0k190.0k381.0k

Interest income

1.0k1.0k2.0k2.0k1.0k1.0k4.0k4.0k12.0k

Pre tax profit

(12.9m)(14.0m)(2.3m)(6.0m)(8.5m)(6.8m)(1.5m)(1.4m)(8.1m)(2.3m)(5.0m)(14.0m)(115.0k)(2.9m)(5.8m)

Income tax expense

Net Income

(12.9m)(14.0m)(2.3m)(6.0m)(8.5m)(6.8m)(1.5m)(1.4m)(8.1m)(2.3m)(5.0m)(14.0m)(115.0k)(2.9m)(5.8m)

Fibrocell Science Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

60.0m37.5m29.3m17.5m17.4m14.4m

Accounts Receivable

Inventories

597.0k1.3m482.0k

Current Assets

61.9m39.3m31.0m18.0m17.9m14.5m

PP&E

1.7m1.6m1.6m1.5m

Total Assets

69.0m45.6m36.7m19.6m19.4m15.8m

Accounts Payable

3.0m1.1m499.0k440.0k862.0k452.0k

Short-term debt

Current Liabilities

3.6m3.5m15.4m3.0m4.4m2.2m

Long-term debt

Total Debt

Total Liabilities

19.3m22.5m11.7m10.4m6.2m

Additional Paid-in Capital

136.7m143.1m161.3m170.4m187.8m198.6m

Retained Earnings

(87.1m)(112.7m)(147.2m)(162.6m)(178.8m)(189.1m)

Total Equity

49.7m14.2m7.9m9.0m9.6m

Financial Leverage

1.4 x2.6 x2.5 x2.2 x1.6 x

Fibrocell Science Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(31.6m)(25.6m)(34.5m)(15.3m)(16.2m)(10.3m)

Depreciation and Amortization

863.0k883.0k767.0k564.0k384.0k392.0k

Accounts Receivable

54.0k12.0k9.0k12.0k

Inventories

(120.0k)26.0k89.0k126.0k

Accounts Payable

2.0m(1.8m)(114.0k)(139.0k)69.0k(24.0k)

Cash From Operating Activities

(20.1m)(22.3m)(24.1m)(29.4m)(17.0m)(12.7m)

Purchases of PP&E

(360.0k)(242.0k)(271.0k)(253.0k)(433.0k)(164.0k)

Cash From Investing Activities

(360.0k)(242.0k)(245.0k)(252.0k)(433.0k)(164.0k)

Dividends Paid

Cash From Financing Activities

49.1m16.1m17.9m17.4m9.9m

Fibrocell Science Ratios

USDY, 2018

Financial Leverage

1.6 x